Rajat Bannerji, MD, PhD
I came to The Cancer Institute of New Jersey (CINJ) in 2012 following six years of conducting clinical research in drug development in the pharmaceutical industry. Prior to joining industry I was in full time clinical practice as a hematologist-oncologist on active duty in the U.S. Army. This included four years as an attending physician at Madigan Army Medical Center preceded by three years of hematology-oncology fellowship training at the Walter Reed Army Medical Center. I completed my internship and residency in internal medicine at the Johns Hopkins Hospital after obtaining a PhD and MD from Cornell.
While I have a clinical focus on the treatment of chronic lymphocytic leukemia (CLL) and the development of novel treatments for this disease, I also evaluate patients with various acute and chronic leukemias, lymphomas, myelodysplastic syndromes, and myeloproliferative diseases. Along with assistance from the multidisciplinary teams within the Leukemia/Lymphoma/Hematologic Malignancies and Stem Cell Transplantation Programs at CINJ, I help educate patients on their treatment options so that they can make an informed decision.
I have a strong research interest in drug development for hematologic malignancies and am currently exploring the use of a novel cyclin dependent kinase (CDK) inhibitor for the treatment of CLL. And by having the resources available that can only be found at a National Cancer Institute-designated Comprehensive Cancer Center, our team is able to translate these research findings and directly apply them to patient therapies.
My interest in drug development began during fellowship when I had the opportunity to work under the mentorship of Dr. John Byrd (an international expert in CLL) investigating the mechanisms of action of rituximab and alemtuzumab in the treatment of CLL. As an attending at Madigan Army Medical Center, I was the principal investigator for a number of cooperative group clinical trials. While working in industry, I led the clinical development of a novel CDK inhibitor from the first-in-humans Phase I trial through Phase II. I have designed and conducted a half dozen clinical trials and hope to use my clinical trials expertise to develop new studies using novel agents for the treatment of CLL and other hematologic cancers.
I am the author or co-author of more than a dozen peer-reviewed publications and more than 20 research meeting presentations (abstracts), as well as a book chapter.
Rajat Bannerji, MD, PhD practices at:
- Main Office
- RWJUH 5 North SDCU
- CINJ- East Tower